By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. (OTLK)

NASDAQ Currency in USD
$1.09
+$0.09
+9.00%
Last Update: 11 Sept 2025, 20:00
$48.42M
Market Cap
-0.82
P/E Ratio (TTM)
Forward Dividend Yield
$0.79 - $6.98
52 Week Range

OTLK Stock Price Chart

Explore Outlook Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze OTLK price movements and trends.

OTLK Company Profile

Discover essential business fundamentals and corporate details for Outlook Therapeutics, Inc. (OTLK) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

14 Jun 2016

Employees

23.00

CEO

Lawrence A. Kenyon CPA

Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK Financial Timeline

Browse a chronological timeline of Outlook Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 May 2026

Upcoming earnings on 26 Dec 2025

EPS estimate is -$0.27.

Earnings released on 14 Aug 2025

EPS came in at -$0.44 falling short of the estimated -$0.42 by -4.76%, while revenue for the quarter reached $1.51M , missing expectations by -77.85%.

Earnings released on 15 May 2025

EPS came in at -$0.40 surpassing the estimated -$0.55 by +27.27%.

Earnings released on 14 Feb 2025

EPS came in at -$0.89 falling short of the estimated -$0.85 by -4.71%.

Earnings released on 27 Dec 2024

EPS came in at -$0.77 surpassing the estimated -$0.83 by +7.23%.

Earnings released on 14 Aug 2024

EPS came in at -$0.83 surpassing the estimated -$1.06 by +21.70%.

Earnings released on 15 May 2024

EPS came in at -$1.55 falling short of the estimated -$0.88 by -76.14%.

Stock split effective on 14 Mar 2024

Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 14 Feb 2024

EPS came in at -$0.80 surpassing the estimated -$1.00 by +20.00%.

Earnings released on 22 Dec 2023

EPS came in at -$1.00 matching the estimated -$1.00.

Earnings released on 14 Aug 2023

EPS came in at -$1.60 falling short of the estimated -$0.80 by -100.00%.

Earnings released on 15 May 2023

EPS came in at -$0.60 surpassing the estimated -$1.20 by +50.00%.

Earnings released on 14 Feb 2023

EPS came in at -$1.60 falling short of the estimated -$0.80 by -100.00%.

Earnings released on 29 Dec 2022

EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.

Earnings released on 10 Aug 2022

EPS came in at -$1.60 matching the estimated -$1.60.

Earnings released on 13 May 2022

EPS came in at -$1.80 falling short of the estimated -$1.40 by -28.57%.

Earnings released on 14 Feb 2022

EPS came in at -$1.60 falling short of the estimated -$1.40 by -14.29%.

Earnings released on 22 Dec 2021

EPS came in at -$1.60 falling short of the estimated -$1.40 by -14.29%.

Earnings released on 13 Aug 2021

EPS came in at -$1.40 surpassing the estimated -$1.60 by +12.50%.

Earnings released on 14 May 2021

EPS came in at -$1.80 surpassing the estimated -$2.20 by +18.18%.

Earnings released on 16 Feb 2021

EPS came in at -$2.20 falling short of the estimated -$0.08 by -2.65K%.

Earnings released on 23 Dec 2020

EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%.

OTLK Stock Performance

Access detailed OTLK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run